Covid-19 Vaccine Effectiveness and the Test-Negative Design

The test-negative design for estimating influenza vaccine effectiveness

Jackson, M. L., & Nelson, J. C. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.053 · Cited by 510

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J. K., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107058 · Cited by 482

Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings

Thompson, M. G., Stenehjem, E. A., Grannis, S. J., Ball, S. W., Naleway, A. L., Ong, T. C., DeSilva, M. B., Natarajan, K., Bozio, C. H., Lewis, N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110362 · Cited by 467

Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness

Sullivan, S. G., Tchetgen, E. J. T., & Cowling, B. J. (2016) · American Journal of Epidemiology · doi:10.1093/aje/kww064 · Cited by 337

Understanding COVID-19 vaccine efficacy

Lipsitch, M., & Dean, N. E. (2020) · Science · doi:10.1126/science.abe5938 · Cited by 230

The Use of Test-negative Controls to Monitor Vaccine Effectiveness

Chua, H., Feng, S., Lewnard, J. A., Sullivan, S. G., Blyth, C. C., Lipsitch, M., & Cowling, B. J. (2019) · Epidemiology · doi:10.1097/ede.0000000000001116 · Cited by 165

Theoretical Framework for Retrospective Studies of the Effectiveness of SARS-CoV-2 Vaccines

Lewnard, J. A., Patel, M. M., Jewell, N. P., Verani, J. R., Kobayashi, M., Tenforde, M. W., Dean, N. E., Cowling, B. J., & Lopman, B. A. (2021) · Epidemiology · doi:10.1097/ede.0000000000001366 · Cited by 103

Test-Negative Designs

Vandenbroucke, J. P., & Pearce, N. E. (2019) · Epidemiology · doi:10.1097/ede.0000000000001088 · Cited by 78

Vaccine effectiveness studies in the field

Evans, S. J. W., & Jewell, N. P. (2021) · New England Journal of Medicine · doi:10.1056/nejme2110605 · Cited by 65

Identifiability and Estimation Under the Test-negative Design With Population Controls With the Goal of Identifying Risk and Preventive Factors for SARS-CoV-2 Infection

Schnitzer, M. E., Harel, D., Ho, V., Koushik, A., & Merckx, J. (2021) · Epidemiology · doi:10.1097/ede.0000000000001385 · Cited by 9

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

Chemaitelly, H., Tang, P., Hasan, M. R., AlMukdad, S., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114114 · Cited by 831

BNT162b2 Protection against the Omicron Variant in Children and Adolescents

Price, A. M., Olson, S. M., Newhams, M. M., Halasa, N., Boom, J. A., Sahni, L. C., Pannaraj, P. S., Irby, K., Bline, K., Maddux, A. B., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202826 · Cited by 229

Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study

Bruxvoort, K. J., Sy, L. S., Qian, L., Ackerson, B. K., Luo, Y., Lee, G. S., Tian, Y., Florea, A., Aragones, M., Tubert, J. E., et al. (2021) · BMJ · doi:10.1136/bmj-2021-068848 · Cited by 230

Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents

Olson, S. M., Newhams, M. M., Halasa, N., Price, A. M., Boom, J. A., Sahni, L. C., Pannaraj, P. S., Irby, K., Walker, T. C., Schwartz, S. P., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2117995 · Cited by 196

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine

Patalon, T., Saciuk, Y., Peretz, A., Perez, G., Lurie, Y., Maor, Y., & Gazit, S. (2022) · Nature Communications · doi:10.1038/s41467-022-30884-6 · Cited by 143

Waning Effectiveness of the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine

Patalon, T., Saciuk, Y., Peretz, A., Perez, G., Lurie, Y., Maor, Y., & Gazit, S. (2022) · doi:10.1101/2022.02.25.22271494 · Cited by 143

Effects of Confounding Bias in Coronavirus Disease 2019 (COVID-19) and Influenza Vaccine Effectiveness Test-Negative Designs Due to Correlated Influenza and COVID-19 Vaccination Behaviors

Doll, M. K., Pettigrew, S. M., Ma, J., & Verma, A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac234 · Cited by 127

Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study

Carazo, S., Skowronski, D. M., Brisson, M., Sauvageau, C., Brousseau, N., Gilca, R., Ouakki, M., Barkati, S., Fafard, J., Talbot, D. C., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00578-3 · Cited by 111

Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil

Ranzani, O., Hitchings, M. D. T., de Melo, R. L., de França, G. V. A., Fernandes, C. D. F. R., Lind, M. L., Torres, M. S. S., Tsuha, D. H., David, L. C. S., Said, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33169-0 · Cited by 112

Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study

Gazit, S., Saciuk, Y., Perez, G., Peretz, A., Pitzer, V. E., & Patalon, T. (2022) · BMJ · doi:10.1136/bmj-2022-071113 · Cited by 87

Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges

Amanatidou, E., Gkiouliava, A., Pella, E., Serafidi, M., Tsilingiris, D., Vallianou, N. G., Karampela, Ι., & Dalamaga, Μ. (2022) · Metabolism Open · doi:10.1016/j.metop.2022.100180 · Cited by 78

Durability of the Single-Dose Ad26.COV2.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge

Polinski, J. M., Weckstein, A. R., Batech, M., Kabelac, C. A., Kamath, T. V., Harvey, R. A., Jain, S., Rassen, J. A., Khan, N. S., & Schneeweiß, S. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.2959 · Cited by 74

Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records

Horne, E. M. F., Hulme, W. J., Keogh, R. H., Palmer, T., Williamson, E., Parker, E. P. K., Green, A. C. A., Walker, V. M., Walker, A. J., Curtis, H. J., et al. (2022) · BMJ · doi:10.1136/bmj-2022-071249 · Cited by 54

Factors Associated With Severe COVID-19 Among Vaccinated Adults Treated in US Veterans Affairs Hospitals

Vo, A. D., La, J., Wu, J. T.-Y., Strymish, J. M., Ronan, M. V., Brophy, M. T., Do, N., Branch‐Elliman, W., Fillmore, N. R., & Monach, P. A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.40037 · Cited by 57

Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study

Rearte, A., Castelli, J. M., Rearte, R., Fuentes, N., Pennini, V., Pesce, M., Barbeira, P. B., Iummato, L. E., Laurora, M., Bartolomeu, M. L., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00011-3 · Cited by 57

Effectiveness of rVSV-ZEBOV vaccination during the 2018–20 Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective test-negative study

Meakin, S. R., Nsio, J. M., Camacho, A., Kitenge, R., Coulborn, R. M., Gignoux, E., Johnson, J. K., Sterk, E., Musenga, E. M., Mustafa, S. H. B., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00419-5 · Cited by 53

Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic

Solante, R., Álvarez, C., Burhan, E., Chariyalertsak, S., Chiu, N., Chuenkitmongkol, S., Dung, D. V., Hwang, K., Ibarra, J. O., Kiertiburanakul, S., et al. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2143347 · Cited by 51

Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA–Vaccinated and Nonvaccinated Individuals in Quebec, Canada

Carazo, S., Skowronski, D. M., Brisson, M., Sauvageau, C., Brousseau, N., Gilca, R., Ouakki, M., Barkati, S., Fafard, J., Talbot, D. C., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.36670 · Cited by 48

Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022

Castillo, M. S., Khaoua, H., & Courtejoie, N. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.16.2200250 · Cited by 45

Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis

Widdifield, J., Kwong, J. C., Chen, S., Eder, L., Benchimol, E. I., Kaplan, G. G., Hitchon, C. A., Aviña-Zubieta, J. A., Lacaille, D. V., Chung, H., et al. (2022) · The Lancet Rheumatology · doi:10.1016/s2665-9913(22)00096-0 · Cited by 43

Estimating protection afforded by prior infection in preventing reinfection: applying the test-negative study design

Ayoub, H. H., Tomy, M., Chemaitelly, H. S., Altarawneh, H. N., Coyle, P. V., Tang, P., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., Butt, A. A., et al. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad239 · Cited by 40

Effectiveness and safety of COVID-19 vaccines on maternal and perinatal outcomes: a systematic review and meta-analysis

Fernández-García, S., del Campo-Albendea, L., Sambamoorthi, D., Sheikh, J., Lau, K. M., Osei-Lah, N., Ramkumar, A., Naidu, H., Stoney, N., Sundaram, P., et al. (2024) · BMJ Global Health · doi:10.1136/bmjgh-2023-014247 · Cited by 46

Association of 2024–2025 Covid-19 Vaccine with Covid-19 Outcomes in U.S. Veterans

Cai, M., Xie, Y., & Al‐Aly, Z. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2510226 · Cited by 43

Double Negative Control Inference in Test-Negative Design Studies of Vaccine Effectiveness

Li, K. Q., Shi, X., Miao, W., & Tchetgen, E. T. (2023) · Journal of the American Statistical Association · doi:10.1080/01621459.2023.2220935 · Cited by 41

Long-term Real-world Protection Afforded by Third mRNA Doses Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections, Coronavirus Disease 19-related Emergency Attendances and Hospitalizations Amongst Older Singaporeans During an Omicron XBB Wave

Wee, L. E., Pang, D., Chiew, C. J., Tan, J. S. H., Lee, V., Ong, B., Lye, D. C., & Tan, K. B. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad345 · Cited by 38

Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine

Cowling, B. J., & Okoli, G. N. (2024) · Drugs · doi:10.1007/s40265-024-02083-8 · Cited by 40

Current Challenges With the Use of Test-Negative Designs for Modeling COVID-19 Vaccination and Outcomes

Shi, X., Li, K. Q., & Mukherjee, B. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac203 · Cited by 33

Effectiveness and protection duration of Covid-19 vaccines and previous infection against any SARS-CoV-2 infection in young adults

Rennert, L., Ma, Z., McMahan, C. S., & Dean, D. (2022) · Nature Communications · doi:10.1038/s41467-022-31469-z · Cited by 31

Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data

Hulme, W. J., Williamson, E., Horne, E. M. F., Green, A. C. A., McDonald, H. I., Walker, A. J., Curtis, H. J., Morton, C. E., MacKenna, B., Croker, R., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m21-4269 · Cited by 30

Tracking immune correlates of protection for emerging SARS-CoV-2 variants

Nilles, E. J., Paulino, C. T., Aubin, M. D. S., Duke, W., Jarolı́m, P., Sánchez, I. M., Murray, K. O., Lau, C. L., Gutiérrez, E. Z., Skewes-Ramm, R., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00001-4 · Cited by 28

Estimands and Estimation of COVID-19 Vaccine Effectiveness Under the Test-Negative Design

Schnitzer, M. E. (2022) · Epidemiology · doi:10.1097/ede.0000000000001470 · Cited by 29

Estimating protection afforded by prior infection in preventing reinfection: Applying the test-negative study design

Ayoub, H. H., Tomy, M., Chemaitelly, H., Altarawneh, H. N., Coyle, P., Tang, P., Hasan, M. R., Kanaani, Z. A., Kuwari, E. A., Butt, A. A., et al. (2022) · doi:10.1101/2022.01.02.22268622 · Cited by 41

Waning of 2-dose BNT162b2 and mRNA-1273 vaccine effectiveness against symptomatic SARS-CoV-2 infection accounting for depletion-of-susceptibles bias

Andrejko, K. L., Pry, J. M., Myers, J. F., Mehrotra, M., Lamba, K., Lim, E., Fukui, N., DeGuzman, J. L., Openshaw, J., Watt, J., et al. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad017 · Cited by 28

The effectiveness of COVID-19 vaccines in Latin America, 2021: a multicenter regional case–control study

Kahn, R. J., Janusz, C. B., Castro, M. C., Matos, A. D. R., Domingues, C. M. A. S., Ponmattam, J., Rey-Benito, G. J., Toscano, C. M., de Oliveira, L. H., Rearte, A., et al. (2023) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2023.100474 · Cited by 27

Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platform

Nguyen, J. L., Mitratza, M., Volkman, H. R., de Munter, L., Tran, T. M. P., Marques, C., Mustapha, M. M., Valluri, S. R., Yang, J., Antón, A., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102995 · Cited by 25

Persistent Health Issues, Adverse Events, and Effectiveness of Vaccines during the Second Wave of COVID-19: A Cohort Study from a Tertiary Hospital in North India

Kaur, U., Bala, S., Joshi, A. U., Reddy, N. T. S., Japur, C., Chauhan, M., Pedapanga, N., Kumar, S., Mukherjee, A., Mishra, V. K., et al. (2022) · Vaccines · doi:10.3390/vaccines10071153 · Cited by 23

Estimated Impact of the US COVID-19 Vaccination Campaign—Getting to 94% of Deaths Prevented

Jones, M., Khader, K., & Branch‐Elliman, W. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.20391 · Cited by 21

COVID-19 Vaccines against Omicron Variant: Real-World Data on Effectiveness

Kherabi, Y., Launay, O., & Nguyen, L. B. L. (2022) · Viruses · doi:10.3390/v14102086 · Cited by 20

COVID-19 vaccination effectiveness rates by week and sources of bias: a retrospective cohort study

Ostropolets, A., & Hripcsak, G. M. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061126 · Cited by 18

BNT162b2 Effectiveness Against Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2 in Adolescents Aged 12–17 Years, by Dosing Interval and Duration

Ionescu, I. G., Skowronski, D. M., Sauvageau, C., Chuang, E., Ouakki, M., Kim, S. H., & Serres, G. D. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad006 · Cited by 22

Typhoid conjugate vaccine effectiveness in Malawi: evaluation of a test-negative design using randomised, controlled clinical trial data

Liang, Y., Driscoll, A. J., Patel, P. D., Datta, S., Voysey, M., French, N., Jamka, L. P., Henrion, M., Ndeketa, L., Laurens, M. B., et al. (2022) · The Lancet Global Health · doi:10.1016/s2214-109x(22)00466-1 · Cited by 19

Effectiveness of Monovalent mRNA Vaccines Against Omicron XBB Infection in Singaporean Children Younger Than 5 Years

Wee, L. E., Tang, N., Pang, D., Chiew, C. J., Yung, C.-F., Chong, C. Y., Lee, V., Ong, B. K. C., Lye, D. C., & Tan, K. B. (2023) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2023.4505 · Cited by 20

Incidence and Estimated Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Among Persons Tested in US Retail Locations, May 1 to August 7, 2021

Tabak, Y. P., Sun, X., Brennan, T. A., & Chaguturu, S. K. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.43346 · Cited by 18

Trends in Risk Factors and Symptoms Associated With SARS-CoV-2 and Rhinovirus Test Positivity in King County, Washington, June 2020 to July 2022

Hansen, C., Perofsky, A. C., Burstein, R., Famulare, M., Boyle, S., Prentice, R. A., Marshall, C., McCormick, B., Reinhart, D., Capodanno, B., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.45861 · Cited by 17

Impact of Vaccination, Prior Infection, and Therapy on Omicron Infection and Mortality

Wang, X., Zein, J., Ji, X., & Lin, D.-Y. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac460 · Cited by 17

Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis

Lind, M. L., Robertson, A. J., Silva, J. D. S., Warner, F. J., Coppi, A. C., Price, N. D., Duckwall, C., Sosensky, P., Giuseppe, E. C. D., Borg, R., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1004136 · Cited by 22

Rates of infection with other pathogens after a positive COVID-19 test versus a negative test in US veterans (November, 2021, to December, 2023): a retrospective cohort study

Cai, M., Xu, E., Xie, Y., & Al‐Aly, Z. (2025) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00831-4 · Cited by 17

Dynamics of Trust and Consumption of COVID-19 Information Implicate a Mechanism for COVID-19 Vaccine and Booster Uptake

Juárez, R., Kang, Z., Okihiro, M. M., Garcia, B. K., Phankitnirundorn, K., & Maunakea, A. K. (2022) · Vaccines · doi:10.3390/vaccines10091435 · Cited by 16

Test negative design for vaccine effectiveness estimation in the context of the COVID-19 pandemic: A systematic methodology review

Mésidor, M., Liu, Y., Talbot, D. C., Skowronski, D. M., Serres, G. D., Merckx, J., Koushik, A., Tadrous, M., Carazo, S., Jiang, C., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.12.013 · Cited by 16

A Shot in the Arm for Vaccination Intention: The Media and the Health Belief Model in Three Chinese Societies

Liu, R., Huang, Y. C., Sun, J., Lau, J., & Cai, Q. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19063705 · Cited by 16

Effectiveness of COVID-19 Viral Vector Ad.26.COV2.S Vaccine and Comparison with mRNA Vaccines in Cirrhosis

John, B. V., Barritt, A. S., Moon, A. M., Taddei, T. H., Kaplan, D. E., Dahman, B. A., Doshi, A., Deng, Y., Mansour, N., Ioannou, G. N., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.05.038 · Cited by 16

mRNA vaccines against COVID‐19: a showcase for the importance of microbial biotechnology

Brüssow, H. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13974 · Cited by 16

On Measuring Vaccine Effectiveness with Observational Study Designs

Habibzadeh, F., Habibzadeh, P., & Yadollahie, M. (2022) · Acta Medica Academica · doi:10.5644/ama2006-124.383 · Cited by 15

Frailty Reduces Vaccine Effectiveness Against SARS-CoV-2 Infection: A Test-Negative Case Control Study Using National VA Data

Tang, F., Hammel, I. S., Andrew, M. K., & Ruiz, J. G. (2023) · The journal of nutrition health & aging · doi:10.1007/s12603-023-1885-1 · Cited by 16

Using negative controls to adjust for unmeasured confounding bias in time series studies

Hu, J. K., Tchetgen, E. J. T., & Dominici, F. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00249-4 · Cited by 16

Potential biases in test-negative design studies of COVID-19 vaccine effectiveness arising from the inclusion of asymptomatic individuals

Ortíz‐Brizuela, E., Carabalí, M., Jiang, C., Merckx, J., Talbot, D. C., & Schnitzer, M. E. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae288 · Cited by 16

Vaccine Effectiveness against SARS-CoV-2 Variants in Adolescents from 15 to 90 Days after Second Dose: A Population-Based Test-Negative Case-Control Study

OLIVEIRA, E. A., Oliveira, M. C. L., Colosimo, E. A., Silva, A. C. S. E., MAK, R. H. K., Vasconcelos, M. A., Silva, L. R., Martelli, D. R. B., Pinhati, C. C., & Martelli‐Júnior, H. (2022) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2022.09.039 · Cited by 14

Vaccine effectiveness and duration of protection against symptomatic infections and severe Covid-19 outcomes in adults aged 50 years and over, France, January to mid-December 2021

Suarez Castillo, M., Khaoua, H., & Courtejoie, N. (2022) · Global Epidemiology · doi:10.1016/j.gloepi.2022.100076 · Cited by 13

Dynamics of Naturally Acquired Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 in Children and Adolescents

Patalon, T., Saciuk, Y., Hadad, H. O., Peretz, A., Peretz, A., Ben‐Tov, A., & Gazit, S. (2023) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2023.02.016 · Cited by 13

Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March–October, 2021

Plumb, I. D., Fette, L. M., Tjaden, A. H., Feldstein, L. R., Saydah, S., Ahmed, A., Link‐Gelles, R., Wierzba, T. F., Berry, A. A., Friedman-Klabanoff, D. J., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.03.006 · Cited by 12

Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study

González, S. E., Olszevicki, S., Gaiano, A., Salazar, M. R., Regairaz, L., Baino, A. N. V., Bartel, E., Varela, T., González, V., Pesci, S. A., et al. (2023) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2023.100607 · Cited by 13

Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany

Dulovic, A., Kessel, B., Harries, M., Becker, M., Ortmann, J., Griesbaum, J., Juengling, J., Junker, D., Hernández, P., Gornyk, D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.828053 · Cited by 12

Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies

Chang, S., Liu, H., Wu, J., Xiao, W., Chen, S., Qiu, S., Duan, G., Song, H., & Zhang, R. (2022) · Vaccines · doi:10.3390/vaccines10030469 · Cited by 12

Use of Whole-Genome Sequencing to Estimate the Contribution of Immune Evasion and Waning Immunity on Decreasing COVID-19 Vaccine Effectiveness

Lind, M. L., Copin, R., McCarthy, S., Coppi, A. C., Warner, F., Ferguson, D. J. P., Duckwall, C., Borg, R., Muenker, M. C., Overton, J. D., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac453 · Cited by 13

Addressing misclassification bias in vaccine effectiveness studies with an application to Covid-19

Eusebi, P., Speybroeck, N., Hartnack, S., Stærk‐Østergaard, J., Denwood, M. J., & Kostoulas, P. (2023) · BMC Medical Research Methodology · doi:10.1186/s12874-023-01853-4 · Cited by 11

Building the U.S. COVID-19 vaccine effectiveness program: Past successes and future directions

Link‐Gelles, R., Britton, A., & Fleming-Dutra, K. E. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.12.002 · Cited by 14

Anti–SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October 2021–June 2022

Sumner, K. M., Yadav, R., Noble, E. K., Sandford, R., Joshi, D., Tartof, S. Y., Wernli, K. J., Martin, E. T., Gaglani, M., Zimmerman, R. K., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae090 · Cited by 10

Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses — IVY Network, September 1, 2022–March 30, 2023

Lewis, N. M., Harker, E. J., Leis, A. M., Zhu, Y., Talbot, H. K., Grijalva, C. G., Halasa, N., Chappell, J. D., Johnson, C. A., Rice, T. W., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126492 · Cited by 10

Effectiveness of a Messenger RNA Vaccine Booster Dose Against Coronavirus Disease 2019 Among US Healthcare Personnel, October 2021–July 2022

Plumb, I. D., Mohr, N. M., Hagen, M., Wiegand, R. E., Dumyati, G. K., Harland, K. K., Krishnadasan, A., James-Gist, J., Abedi, G. R., Fleming-Dutra, K. E., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad457 · Cited by 12

Declining Levels of Neutralizing Antibodies to SARS-CoV-2 Omicron Variants Are Enhanced by Hybrid Immunity and Original/Omicron Bivalent Vaccination

Walmsley, S. L., Nabipoor, M., Qi, F., Lovblom, L. E., Ravindran, R., Colwill, K., Dayam, R. M., Tursun, T. R., Silva, A., Gingras, A., et al. (2024) · Vaccines · doi:10.3390/vaccines12060564 · Cited by 10

SARS-CoV-2 vaccination, ABO blood group and risk of COVID-19: population-based cohort study

Ray, J. G., & Park, A. L. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-059944 · Cited by 9

Uncovering associations between pre-existing conditions and COVID-19 Severity: A polygenic risk score approach across three large biobanks

Fritsche, L. G., Nam, K., Du, J., Kundu, R., Salvatore, M., Shi, X., Lee, S., Burgess, S., & Mukherjee, B. (2023) · PLoS Genetics · doi:10.1371/journal.pgen.1010907 · Cited by 12

Evaluating real-world COVID-19 vaccine effectiveness using a test-negative case–control design

Reynolds, M. W., Secora, A. M., Joules, A., Albert, L., Brinkley, E., Kwon, T., Mack, C. D., Toovey, S., & Dreyer, N. A. (2022) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2022-0069 · Cited by 9

Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021

Embí, P. J., Levy, M. E., Patel, P. Y., DeSilva, M. B., Gaglani, M., Dascomb, K. K., Dunne, M. M., Klein, N. P., Ong, T. C., Grannis, S. J., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.05.038 · Cited by 9

Assessing the real-world effectiveness of five SARS-CoV-2 vaccines in a cohort of Mexican pensioners: a nationwide nested test-negative design study

Hernández‐Ávila, M., Ortíz‐Brizuela, E., Tamayo‐Ortiz, M., Zepeda‐Tello, R., Gutiérrez-Díaz, H. O., Cordera, D. B. S., Vieyra-Romero, W. I., Real-Ornelas, G. A., Méndez-Aranda, M., & Gómez, A. H. (2023) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2023.100612 · Cited by 9

Effectiveness of SARS‐CoV‐2‐inactivated vaccine and the correlation to neutralizing antibodies: A test‐negative case–control study

Liu, C., Zhang, J., Zeng, Y., Huang, C., Chen, F., Cao, Y., Wu, S., Wei, D., Lin, Z., Zhang, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28280 · Cited by 6

Vaccinating against a Novel Pathogen: A Critical Review of COVID-19 Vaccine Effectiveness Evidence

Black, B. S., & Thaw, D. B. (2023) · Microorganisms · doi:10.3390/microorganisms12010089 · Cited by 9

Estimates of vaccine effectiveness of the updated monovalent XBB.1.5 COVID-19 vaccine against symptomatic SARS-CoV-2 infection, hospitalization, and receipt of oxygen therapy in South Korea - October 26 to December 31, 2023

Lee, J. A., Jang, H., Ahn, S. M., Seong, J. E., Kim, Y. K., Sohn, Y., Jung, S., Jeong, H. W., Kim, S., Lee, J. S., et al. (2024) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2024.107249 · Cited by 8

COVID-19 vaccine effectiveness against SARS-CoV-2-confirmed hospitalisation in the eastern part of the WHO European Region (2022–2023): a test-negative case-control study from the EuroSAVE network

Katz, M. A., Cohuet, S., Bino, S., Tarkhan‐Mouravi, O., Kryeziu, B., Otorbaeva, D., Stavridis, K., Stošić, M., Sulo, J., Machablishvili, A., et al. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101095 · Cited by 8

Effect of SARS-CoV-2 Infection and Infection Severity on Longer-Term Glycemic Control and Weight in People With Type 2 Diabetes

Wong, R., Vaddavalli, R., Hall, M. A., Patel, M. V., Bramante, C. T., Casarighi, E., Johnson, S., Lingam, V., Miller, J. D., Reusch, J. E. B., et al. (2022) · Diabetes Care · doi:10.2337/dc22-0730 · Cited by 8

Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting

Rane, M. S., Robertson, M. M., Kulkarni, S., Frogel, D., Gainus, C., & Nash, D. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.12.039 · Cited by 7

Estimating COVID-19 Vaccination and Booster Effectiveness Using Electronic Health Records From an Academic Medical Center in Michigan

Roberts, E., Gu, T., Wagner, A. L., Mukherjee, B., & Fritsche, L. G. (2022) · AJPM Focus · doi:10.1016/j.focus.2022.100015 · Cited by 9

Changing patterns of SARS-CoV-2 infection through Delta and Omicron waves by vaccination status, previous infection and neighbourhood deprivation: a cohort analysis of 2.7 M people

Green, M. A., Hungerford, D., Hughes, D. M., García‐Fiñana, M., Turtle, L. C. W., Cheyne, C. P., Ashton, M., Leeming, G., Semple, M. G., Singleton, A. D., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07878-2 · Cited by 7

Effectiveness of BNT162b2 and CoronaVac vaccines against omicron in children aged 5 to 11 years

OLIVEIRA, E. A., Oliveira, M. C. L., Silva, A. C. S. E., Colosimo, E. A., MAK, R. H. K., Vasconcelos, M. A., Silva, L. R., Martelli, D. R. B., Pinhati, C. C., & Martelli‐Júnior, H. (2023) · World Journal of Pediatrics · doi:10.1007/s12519-023-00699-6 · Cited by 9

Bivalent mRNA vaccine effectiveness against COVID-19 among older adults in Japan: a test-negative study from the VENUS study

Tamada, Y., Takeuchi, K., Kusama, T., Maeda, M., Murata, F., Osaka, K., & Fukuda, H. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09035-3 · Cited by 7

Bias-interpretability Trade-offs in Vaccine Effectiveness Studies Using Test-negative or Cohort Designs

Schnitzer, M. E., Ortíz‐Brizuela, E., Carabalí, M., & Talbot, D. C. (2023) · Epidemiology · doi:10.1097/ede.0000000000001708 · Cited by 7

Evaluation of test-negative design estimates of influenza vaccine effectiveness in the context of multiple, co-circulating, vaccine preventable respiratory viruses

Leis, A. M., Wagner, A. L., Flannery, B. L., Chung, J. R., Monto, A. S., & Martin, E. T. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126493 · Cited by 6

Covid-19 vaccine effectiveness against general SARS-CoV-2 infection from the omicron variant: A retrospective cohort study

Rennert, L., Ma, Z., McMahan, C. S., & Dean, D. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001111 · Cited by 6

The role of occupation in SARS‐CoV‐2 infection within a Brazilian municipality: A test‐negative case‐control study

Menezes, F. D. S., García, L. P., Maeno, M., Prearo, L. C., Toporcov, T. N., & Algranti, E. (2023) · American Journal of Industrial Medicine · doi:10.1002/ajim.23542 · Cited by 6

Evaluation of BNT162b2 Vaccine Effectiveness in Galicia, Northwest Spain

Pardo‐Seco, J., Mallah, N., López‐Pérez, L., González-Pérez, J. M., Rosón, B., Otero‐Barrós, M., Durán‐Parrondo, C., Rodrı́guez-Tenreiro, C., Calle, I. R., Gómez‐Carballa, A., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19074039 · Cited by 6

The added effect of non-pharmaceutical interventions and lifestyle behaviors on vaccine effectiveness against severe COVID-19 in Chile: A matched case-double control study

Urquidi, C., Santelices, E., Lagomarcino, A. J., Valenzuela, M. T., Larrañaga, N., Gonzalez, E., Axel Pavez, R., Wosiack, A., Maturana, M., Moller, P., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.03.060 · Cited by 5

A review of airport accessibility programs for individuals diagnosed with autism spectrum disorders: Recommendations for the development of a program at portland international airport

Skillicorn, K. N. (2013) · CommonKnowledge Research Repository (Pacific University Oregon) · Cited by 5

Risk Factors and Incidence Rates of Covid-19 Breakthrough Infections in Vaccinated People in General Medicine Practice in Toledo (Spain)

Luis, T. J. (2022) · Archives of Family Medicine and General Practice · doi:10.36959/577/505 · Cited by 5

Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case–Control Study

Alkadi, M. M., Hamad, A., Ghazouani, H., Elshirbeny, M. F., Ali, M. Y., Ghonimi, T. A. L., Ibrahim, R., Abuhelaiqa, E. A., Abou‐Samra, A., Al-Malki, H. A., et al. (2022) · Vaccines · doi:10.3390/vaccines11010049 · Cited by 5

Role of vaccine in fighting the variants of COVID-19

Wang, J., Jiang, W., Wu, X., Yang, M., & Shao, W. (2023) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2023.113159 · Cited by 5

Over- and under-estimation of vaccine effectiveness

De-Leon, H., & Aran, D. (2025) · BMC Medical Research Methodology · doi:10.1186/s12874-025-02611-4 · Cited by 6

Poor Uptake of MMR Vaccine 1-year Post-Measles Outbreak: New York City and Israel

Paret, M., Trillo, R., Lighter, J., Youngster, I., Ratner, A. J., & Madan, R. P. (2022) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piac026 · Cited by 4

Comparison of the effectiveness of four SARS-COV-2 v accines in Nuevo Leon, Mexico: A test-negative control study

Salinas-Martínez, A. M., Vidales, E. P. R., Garza‐Carrillo, D., Robles‐Rodríguez, O. A., Montes‐de‐Oca‐Luna, R., & Marroquín-Escamilla, A. R. (2023) · Atención Primaria · doi:10.1016/j.aprim.2023.102606 · Cited by 5

Measuring vaccine protection when the population is mostly vaccinated

Goldberg, Y., Amir, O., Mandel, M., Freedman, L. S., Bar‐On, Y. M., Bodenheimer, O., Milo, R., & Huppert, A. (2023) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2023.09.009 · Cited by 4

Effectiveness of COVID-19 vaccines in Ecuador: A test-negative design

Pérez‐Tasigchana, R. F., Valcárcel-Pérez, I., Arias-Quispe, M., Astudillo, L., Bruno, A., Marco Herrera, G., Armas-González, R., de Mora, D., Pinos, J., Olmedo, A., et al. (2023) · Vaccine X · doi:10.1016/j.jvacx.2023.100404 · Cited by 6

Test-Negative Study Designs for Evaluating Vaccine Effectiveness

Dean, N. E., & Amin, A. B. (2024) · JAMA · doi:10.1001/jama.2024.5633 · Cited by 15

The Test-Negative Design for Assessing Vaccine Effectiveness.

Jewell, N. P. (2026) · PubMed · doi:10.2105/ajph.2026.308764

On Measuring Vaccine Effectiveness with Observational Study Designs

Habibzadeh, F., Habibzadeh, P., & Yadollahie, M. (2022) · Acta Medica Academica · doi:10.5644/ama2006-124.383 · Cited by 15

Evaluating COVID-19 vaccine effectiveness across epidemiologic designs: test-negative case-control versus retrospective cohort analyses in a nationwide study

Sukik, L., Paul, P., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., et al. (2026) · International Journal of Epidemiology · doi:10.1093/ije/dyag210

Proposed study design for estimating COVID-19 vaccine effectiveness in post-pandemic Taiwan

Chen, L. Y., Lee, C.-Y., Kuo, H.-W., Liu, Y. C., & Chuang, J.-H. (2026) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001372